LifeSensors last week launched its Chop2 Reporter Assay Kits for deubiquitylases and announced the "imminent launch" of its ubiquitin ligase assay kits.
The technologies are licensed from Progenra which developed them.
In a statement, LifeSensors said that the conjugation and deconjugation of ubiquitin and ubiquitin-like proteins are of "intense" interest to academia and pharma "due to their central roles in human health and disease," and research in such pathways are likely to lead to "many pioneering drugs."
Benefits of the Chop2 Reporter Assay Kits include sensitive, rapid, and robust fluorescent readouts of enzymatic activity within a half-hour with "minimal interference from screening compounds," the company said.
Malvern, Penn.-based LifeSensors specializes in protein expression technologies, ubiquitin pathway research tools, and protein microarrays.
AnaSpec last week launched the Z-Fish series of antibodies, raised strictly from peptide antigens derived from zebrafish protein sequences.
The antigens used in raising the antibodies include non-phosphorylated and phosphorylated peptides. The antibodies are available in 150 microliter size, which is optimal for 15 mini gels, AnaSpec said.
The antibodies being released are for MMP-2, 9, 11, 13, 14, 17, and 24 and were raised from sequences derived from the hinge region, internal, or C-terminal sequence. Other Z-Fish antibodies that will be released soon are for MMP-18 (IN), MMP-18 (hinge), MMP-21 (IN), and MMP-28 (hinge).